Table 1.
Baseline characteristics of cases and controls.
| Outcomes | Infection | Hospitalization | Severe COVID-19 | |||
|---|---|---|---|---|---|---|
| Cases | Controls | Cases | Controls | Cases | Controls | |
| Number of individuals | 36,434 | 109,004 | 2231 | 21,788 | 1918 | 18,823 |
| Age, years (mean (SD)) | 10.35 (4.00) | 10.35 (4.00) | 8.70 (4.38) | 8.67 (4.38) | 8.53 (4.31) | 8.50 (4.30) |
| Sex, male (%) | 20766 (57.0) | 62211 (57.1) | 1283 (57.5) | 12561 (57.7) | 1106 (57.7) | 10871 (57.8) |
| Charlson Comorbidity Index (mean (SD)) | 0.03 (0.19) | 0.03 (0.18) | 0.07 (0.34) | 0.03 (0.20) | 0.05 (0.30) | 0.03 (0.19) |
| Time since recent dose (mean (SD)) | 88.72 (80.59) | 75.75 (80.79) | 85.07 (67.14) | 81.05 (72.60) | 84.41 (66.22) | 79.38 (69.90) |
| Comorbidities – no. (%) | ||||||
| Asthma | 789 (2.2) | 1955 (1.8) | 53 (2.4) | 467 (2.1) | 40 (2.1) | 333 (1.8) |
| Diabetes | 45 (0.1) | 251 (0.2) | 9 (0.4) | 46 (0.2) | 7 (0.4) | 32 (0.2) |
| Epilepsy | 237 (0.7) | 1961 (1.8) | 83 (3.7) | 200 (0.9) | 77 (4.0) | 180 (1.0) |
| Medication use within 90 days – no. (%) | ||||||
| Immunosuppressants | 36 (0.1) | 223 (0.2) | 13 (0.6) | 43 (0.2) | 9 (0.5) | 37 (0.2) |